Integrated therapy for HIV and tuberculosis.

Area of Science:

• Infectious Diseases
• Public Health
• Immunology

Background:

• Tuberculosis (TB) is a leading opportunistic infection and cause of mortality in HIV-infected individuals, particularly in resource-limited settings.
• Clinical TB presentation varies with immunodeficiency levels, and diagnosis relies on sputum microscopy, culture, and drug-susceptibility testing.
• High TB-related mortality in HIV patients, especially early in treatment, necessitates effective management strategies.

Purpose of the Study:

• To evaluate the feasibility and efficacy of integrated human immunodeficiency virus (HIV) and tuberculosis (TB) therapy.
• To determine optimal timing for initiating antiretroviral therapy (ART) in HIV-infected patients with TB.
• To highlight the importance of managing adverse drug reactions and immune reconstitution inflammatory syndrome (IRIS) in co-infected patients.

Main Methods:

• Review of randomized clinical trials and clinical guidelines on integrated HIV and TB management.
• Analysis of standard TB treatment regimens and recommended ART regimens, including preferred drugs like efavirenz.
• Emphasis on diagnostic methods for active TB and monitoring of immune status (CD4 cell count).

Main Results:

• Integrated HIV and TB care in a single facility with a single provider is an effective model for disease control and improved survival.
• Early ART initiation significantly improves survival; delays are associated with increased mortality risk.
• Standard TB treatment regimens are recommended for HIV-infected patients, with ART initiated within 8 weeks of TB treatment (or 2 weeks if CD4 <50 cells/mm³).

Conclusions:

• Integrated therapy for HIV and TB is feasible and efficient, leading to better patient survival.
• Early initiation of ART is critical for improving outcomes in HIV-infected patients with TB.
• Close monitoring and management of adverse events and IRIS are essential for successful integrated HIV-TB care.